Everything below concerns GLP-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
=== First Empire === September 15, 1807: If a husband goes bankrupt, the wife's personal assets are also affected. March 17, 1808: Decree organizing the university bans women from entering colleges or lycées. March 29, 1809: Decree organizing Napoleon's imperial houses in Écouen and Saint-Denis to educate battlefield orphans' daughters as "future mothers." 1810: Penal Code of 1810 includes measures specific to women or differentiates penalties by sex. January 19, 1811: Decree on foundlings, abandoned children, and poor orphans, with education differing by sex. October 15, 1812: Decree on the Théâtre-Français's oversight, organization, administration, accounting, police, and discipline, admitting equal numbers of male and female students. February 5, 1813: Organic Senatus-Consultum on imperial regency and the coronation of the empress and prince imperial, prioritizing the empress for regency and barring her remarriage.
Although these patients were historically classified as having DM, they are now generally considered to have the distinct clinical entity antisynthetase syndrome, even in the presence of characteristic cutaneous features. Magnetic resonance imaging may be useful for guiding muscle biopsy and for distinguishing active inflammation from irreversible muscle damage as contributors to muscle weakness. In addition to muscle inflammation, MRI frequently demonstrates fascial inflammation (fasciitis) in patients with DM. X-ray may be used to investigate joint involvement and calcifications. A case of DM may be classified as clinically amyopathic dermatomyositis (CADM) when cutaneous manifestations predominate and there is little or no clinical evidence of muscle involvement. Anti-MDA5 autoantibodies are strongly associated with CADM and are frequently accompanied by rapidly progressive interstitial lung disease. Patients with anti-TIF1-γ autoantibodies also commonly present with clinically amyopathic disease, although less frequently than those with anti-MDA5 autoantibodies. Juvenile dermatomyositis (JDM) has traditionally been regarded as a distinct entity from adult-onset DM. However, there is no convincing evidence that the two differ fundamentally in their pathophysiology, and they are now generally considered age-specific presentations of the same group of conditions.
It allows for the highest levels of exercise intensity, but intramuscular stores of phosphocreatine are very limited and can only provide energy for exercises lasting up to ten seconds. Recovery is very quick, with full creatine stores regenerated within five minutes.
Sources: en.wikipedia.org
The main approach to managing BPD is through psychotherapy, with a few different interventions having demonstrated a reduction in symptoms and an increase in well-being. While medications do not directly treat BPD, they are beneficial in managing comorbid conditions like depression and anxiety. Evidence states short-term hospitalization does not offer advantages over community care in terms of enhancing outcomes or in the long-term prevention of suicidal behavior among individuals with BPD.
As part of Operation Typhoon, the 4th Panzer Group was subordinated to the 4th Army under the command of Günther von Kluge. In early October, the 4th Panzer Group completed the encirclement at Vyazma. Kluge instructed Hoepner to pause the advance, much to the latter's displeasure, as his units were needed to prevent break-outs of Soviet forces. Hoepner was confident that the clearing of the pocket and the advance on Moscow could be undertaken at the same time and viewed Kluge's actions as interference, leading to friction and "clashes" with his superior, as he wrote in a letter home on 6 October. Hoepner did not seem to appreciate that his units were very short on fuel; the 11th Panzer Division, reported having no fuel at all. Only the 20th Panzer Division was advancing towards Moscow amid deteriorating road conditions. Once the Vyazma pocket was eliminated, other units were able to advance on 14 October. Heavy rains and onset of the rasputitsa (roadlessness) caused frequent damage to tracked vehicles and motor transport further hampering the advance. By early November, the 4th Panzer Group was depleted from earlier fighting and the weather but Hoepner, along with other panzer group commanders and Fedor von Bock, commander of Army Group Center, was impatient to resume the offensive. On 17 November, the 4th Panzer Group attacked again towards Moscow alongside the V Army Corps of the 4th Army, as part of the continuation of Operation Typhoon by Army Group Centre. The panzer group and the army corps represented Kluge's best forces, most ready for a continued offensive.
Many metals such as the alkali metals react directly with the electronegative halogens gases to form salts. Solid salts can form upon evaporation of solvent from their solutions once the solution is supersaturated and the solid compound nucleates. This process occurs widely in nature and is the means of formation of the evaporite minerals. Insoluble salts can be precipitated by mixing two solutions, one containing the cation and one containing the anion. Because all solutions are electrically neutral, the two solutions mixed must also contain counterions of the opposite charges. To ensure that these do not contaminate the precipitated salt, it is important to ensure they do not also precipitate. If the two solutions have hydrogen ions and hydroxide ions as the counterions, they will react with one another in what is called an acid–base reaction or a neutralization reaction to form water. Alternately the counterions can be chosen to ensure that even when combined into a single solution they will remain soluble as spectator ions. If the solvent is water in either the evaporation or precipitation method of formation, in many cases the ionic crystal formed also includes water of crystallization, so the product is known as a hydrate, and can have very different chemical properties compared to the anhydrous material. Molten salts will solidify on cooling to below their freezing point. This is sometimes used for the solid-state synthesis of complex salts from solid reactants, which are first melted together.
Sources: en.wikipedia.org
"You Hurled Me Into the Depths, Into the Very Heart of the Seas" is the second episode of the fourth season of the American dark comedy crime television series The Righteous Gemstones. It is the 29th overall episode of the series and was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. It was released on HBO on March 16, 2025, and also was available on Max on the same date. The series follows a family of televangelists and megachurch pastors led by widowed patriarch Eli Gemstone. The main focus is Eli and his immature children, Jesse, Kelvin and Judy, all of whom face challenges in their lives. The series depicts the family's past and scandals, which unleash consequences. In the episode, the Gemstones try to locate a missing Elijah for a telethon. According to Nielsen Media Research, the episode was seen by an estimated 0.264 million household viewers and gained a 0.05 ratings share among adults aged 18–49. The episode received mostly positive reviews from critics, who praised its humor, performances and character development.
Signs and symptoms which (a) are suggestive of a connective tissue disease, but (b) do not meet the criteria of any defined connective tissue diseases, and (c) have lasted for at least three years. (Note, if less than three years, may be regarded as early UCTD). Positive ANA test on two different occasions.
Glucokinase activity can be amplified or reduced in minutes by actions of the glucokinase regulatory protein (GKRP). The actions of this protein are influenced by small molecules such as glucose and fructose. The amount of glucokinase can be increased by synthesis of new protein. Insulin is the principal signal for increased transcription, operating mainly by way of a transcription factor called sterol regulatory element binding protein-1c (SREBP1c) in the liver. This occurs within an hour after a rise in insulin levels, as after a carbohydrate meal.
Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication used to treat skin diseases like harlequin-type ichthyosis, lamellar ichthyosis, and severe cystic acne or moderate acne that is unresponsive to antibiotics. Isotretinoin is used off-label to treat basal cell carcinoma and squamous cell carcinoma, although clinical evidence suggests it is not effective in this setting. It is a retinoid, meaning it is related to vitamin A, and is found in small quantities naturally in the body. Its isomer, tretinoin, is also an acne drug. In its pure form, isotretinoin is an orange powder. The most common adverse effects are dry lips (cheilitis), dry and fragile skin (xeroderma), dry eyes and an increased susceptibility to sunburn. Uncommon and rare side effects include muscle aches and pains (myalgias), headaches, and depression in some users. Some of those side effects can persist long after the discontinuation of the use of the drug. Isotretinoin may cause liver failure, therefore the patient's blood levels should be regularly tested. It is known to cause birth defects due to in-utero exposure because of the molecule's close resemblance to retinoic acid, a natural vitamin A derivative that controls normal embryonic development. It is associated with psychiatric side effects, most commonly depression, and more rarely, psychosis and unusual behaviors. Other rare side effects include hyperostosis and premature epiphyseal closure, which have been reported to be persistent.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.